Profile data is unavailable for this security.
About the company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
- Revenue in USD (TTM)56.04m
- Net income in USD-146.78m
- Incorporated2008
- Employees165.00
- LocationEyePoint Pharmaceuticals Inc480 Pleasant Street, Suite C400WATERTOWN 02472United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050
- Websitehttps://eyepointpharma.com/